From the Guidelines
Finasteride (Badrostat) has no established relationship with Chronic Kidney Disease (CKD) progression or treatment, and its use should not be considered a factor in CKD management. The provided evidence does not mention Finasteride (Badrostat) in the context of CKD management or progression. Instead, it focuses on the management of diabetic kidney disease (DKD) and CKD, highlighting the importance of early detection, blood pressure control, glucose management, and the use of SGLT2 inhibitors, GLP-1 receptor agonists, and finerenone for reducing the risk of kidney disease progression and cardiovascular events 1. Key points to consider in CKD management include:
- Early detection and initiation of proven interventions to prevent disease progression and complications
- Blood pressure control with ACE inhibitors or ARBs
- Glucose management in diabetic patients
- Use of SGLT2 inhibitors, such as dapagliflozin or empagliflozin, for their kidney and cardiovascular protective benefits
- Consideration of finerenone for appropriate candidates to mitigate CKD progression and cardiovascular risks Given the lack of evidence linking Finasteride (Badrostat) to CKD management, the focus should remain on established treatments with proven benefits for slowing CKD progression and reducing cardiovascular risks 1.
From the Research
Relationship Between Badrostat (Finasteride) and Chronic Kidney Disease (CKD)
There are no research papers provided that directly investigate the relationship between Badrostat (Finasteride) and Chronic Kidney Disease (CKD). The studies provided focus on the effects of Bardoxolone Methyl, Angiotensin-Converting Enzyme Inhibitors (ACEi), and Angiotensin Receptor Blockers (ARB) on CKD, but do not mention Badrostat (Finasteride) 2, 3, 4, 5, 6.
Effects of Other Medications on CKD
- Bardoxolone Methyl has been shown to increase estimated glomerular filtration rate (eGFR) in patients with CKD associated with type 2 diabetes mellitus 2, 3.
- ACEi and ARB have been found to have beneficial effects on renal outcomes and survival in people with CKD, but their effectiveness in early CKD (stage 1 to 3) is less certain 4, 6.
- The use of ACEi and ARB in patients with early CKD who do not have diabetes mellitus has been found to have insufficient evidence to determine their effectiveness 6.
Limitations of Current Research
- Current research on CKD has focused on the use of ACEi and ARB, but there is a need for more research on other potential treatments, including Badrostat (Finasteride) 5.
- The mechanisms of CKD progression are complex and multifactorial, and more research is needed to fully understand the relationships between different pathways and treatments 5.